1. Home
  2. GIPR vs CPHI Comparison

GIPR vs CPHI Comparison

Compare GIPR & CPHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Generation Income Properties Inc.

GIPR

Generation Income Properties Inc.

HOLD

Current Price

$0.36

Market Cap

3.1M

Sector

Real Estate

ML Signal

HOLD

Logo China Pharma Holdings Inc.

CPHI

China Pharma Holdings Inc.

N/A

Current Price

$0.56

Market Cap

6.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GIPR
CPHI
Founded
2015
N/A
Country
United States
China
Employees
4
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1M
6.1M
IPO Year
N/A
2008

Fundamental Metrics

Financial Performance
Metric
GIPR
CPHI
Price
$0.36
$0.56
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
98.3K
18.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
70.33
EPS
N/A
N/A
Revenue
N/A
$4,528,929.00
Revenue This Year
$1.12
N/A
Revenue Next Year
$0.52
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.37
$0.12
52 Week High
$1.99
$14.00

Technical Indicators

Market Signals
Indicator
GIPR
CPHI
Relative Strength Index (RSI) 28.41 27.42
Support Level N/A N/A
Resistance Level $0.87 $1.88
Average True Range (ATR) 0.06 0.05
MACD -0.01 0.02
Stochastic Oscillator 0.00 19.86

Price Performance

Historical Comparison
GIPR
CPHI

About GIPR Generation Income Properties Inc.

Generation Income Properties Inc is an internally managed real estate investment company focused on acquiring and managing income-producing retail, office and industrial properties net leased to high-quality tenants in markets throughout the United States. Its key source of revenue is the rental income. The company holds properties in Alabama, Arizona, Colorado, the District of Columbia, Florida, Illinois, North Carolina and Virginia.

About CPHI China Pharma Holdings Inc.

China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection and others.

Share on Social Networks: